{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:08:19Z","timestamp":1785319699611,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-01583-1","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:33:28Z","timestamp":1747157608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A pharmacovigilance analysis of post-marketing safety of durvalumab"],"prefix":"10.1038","volume":"15","author":[{"given":"An-Ju","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Li","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dun-Chang","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"1583_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","volume":"147","author":"R Kramer","year":"2021","unstructured":"Kramer, R. et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur. J. Cancer. 147, 170\u2013181. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.013 (2021).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"1583_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11096-023-01678-7","volume":"46","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Exploring the safety profile of Tremelimumab: an analysis of the FDA adverse event reporting system. Int. J. Clin. Pharm. 46 (2), 480\u2013487. https:\/\/doi.org\/10.1007\/s11096-023-01678-7 (2024).","journal-title":"Int. J. Clin. Pharm."},{"key":"1583_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741 (2021).","journal-title":"Annu. Rev. Pathol."},{"issue":"9","key":"1583_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart, R. et al. Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol. Res. 3 (9), 1052\u20131062. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0191 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"1583_CR5","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed, Y. Y. & Durvalumab First global approval. Drugs 77 (12), 1369\u20131376. https:\/\/doi.org\/10.1007\/s40265-017-0782-5 (2017).","journal-title":"Drugs"},{"issue":"12","key":"1583_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14737140.2019.1699407","volume":"19","author":"S Murakami","year":"2019","unstructured":"Murakami, S. Durvalumab for the treatment of non-small cell lung cancer. Expert Rev. Anticancer Ther. 19 (12), 1009\u20131016. https:\/\/doi.org\/10.1080\/14737140.2019.1699407 (2019).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"5","key":"1583_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/onco.13752","volume":"26","author":"L Mathieu","year":"2021","unstructured":"Mathieu, L. et al. FDA approval summary: Atezolizumab and durvalumab in combination with Platinum-Based chemotherapy in extensive stage small cell lung Cancer. Oncologist 26 (5), 433\u2013438. https:\/\/doi.org\/10.1002\/onco.13752 (2021).","journal-title":"Oncologist"},{"issue":"2","key":"1583_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","volume":"30","author":"TH Patel","year":"2024","unstructured":"Patel, T. H. et al. FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin. Cancer Res. 30 (2), 269\u2013273. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2124 (2024).","journal-title":"Clin. Cancer Res."},{"issue":"7\u20138","key":"1583_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bulcan.2023.04.004","volume":"110","author":"L Blondet","year":"2023","unstructured":"Blondet, L. & Sarabi, M. [New drug approval: durvalumab in combinaison with cisplatin and gemcitabine in first-line in patient with advanced biliary tract cancer]. Bull. Cancer. 110 (7\u20138), 742\u2013744. https:\/\/doi.org\/10.1016\/j.bulcan.2023.04.004 (2023).","journal-title":"Bull. Cancer"},{"issue":"6","key":"1583_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11523-023-01007-y","volume":"18","author":"S Fung","year":"2023","unstructured":"Fung, S., Syed, Y. Y. & Durvalumab A review in advanced biliary tract Cancer. Target. Oncol. 18 (6), 965\u2013972. https:\/\/doi.org\/10.1007\/s11523-023-01007-y (2023).","journal-title":"Target. Oncol."},{"issue":"10","key":"1583_CR11","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.jtho.2019.06.010","volume":"14","author":"SJ Antonia","year":"2019","unstructured":"Antonia, S. J. et al. Clinical activity, tolerability, and Long-Term Follow-Up of durvalumab in patients with advanced NSCLC. J. Thorac. Oncol. 14 (10), 1794\u20131806. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.010 (2019).","journal-title":"J. Thorac. Oncol."},{"issue":"20","key":"1583_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III Non-Small-Cell lung Cancer. N Engl. J. Med. 377 (20), 1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937 (2017).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"1583_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","volume":"19","author":"MC Garassino","year":"2018","unstructured":"Garassino, M. C. et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 19 (4), 521\u2013536. https:\/\/doi.org\/10.1016\/S1470-2045(18)30144-X (2018).","journal-title":"Lancet Oncol."},{"issue":"1","key":"1583_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman, J. W. et al. Durvalumab, with or without Tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 22 (1), 51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8 (2021).","journal-title":"Lancet Oncol."},{"issue":"6","key":"1583_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson, M. L. et al. Durvalumab with or without Tremelimumab in combination with chemotherapy as First-Line therapy for metastatic Non-Small-Cell lung cancer: the phase III POSEIDON study. J. Clin. Oncol. 41 (6), 1213\u20131227. https:\/\/doi.org\/10.1200\/JCO.22.00975 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"1583_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris","year":"2024","unstructured":"Burris, H. A. 3 et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 25 (5), 626\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(24)00082-2 (2024).","journal-title":"Lancet Oncol."},{"issue":"29","key":"1583_CR17","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst, R. S. et al. An Open-Label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or Monalizumab in patients with unresectable, stage III Non-Small-Cell lung Cancer. J. Clin. Oncol. 40 (29), 3383\u20133393. https:\/\/doi.org\/10.1200\/JCO.22.00227 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"1583_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro, B. et al. Four-year overall survival update from the phase III HIMALAYA study of Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 35 (5), 448\u2013457. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.005 (2024).","journal-title":"Ann. Oncol."},{"issue":"3","key":"1583_CR19","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","volume":"12","author":"Y Shu","year":"2023","unstructured":"Shu, Y. et al. Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med. 12 (3), 3365\u20133375. https:\/\/doi.org\/10.1002\/cam4.5062 (2023).","journal-title":"Cancer Med."},{"issue":"1","key":"1583_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 11 (1), 3\u201310. https:\/\/doi.org\/10.1002\/pds.668 (2002).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"1583_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10 (6), 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"1583_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54 (4), 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"1583_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman, A., Machado, S. G. & O\u2019Neill, R. T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 25 (6), 381\u2013392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001 (2002).","journal-title":"Drug Saf."},{"key":"1583_CR24","doi-asserted-by":"publisher","first-page":"1169735","DOI":"10.3389\/fimmu.2023.1169735","volume":"14","author":"Y Shu","year":"2023","unstructured":"Shu, Y., Chen, J., Ding, Y. & Zhang, Q. Adverse events with Risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front. Immunol. 14, 1169735. https:\/\/doi.org\/10.3389\/fimmu.2023.1169735 (2023).","journal-title":"Front. Immunol."},{"key":"1583_CR25","doi-asserted-by":"publisher","first-page":"1103927","DOI":"10.3389\/fphar.2023.1103927","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies. Front. Pharmacol. 14, 1103927. https:\/\/doi.org\/10.3389\/fphar.2023.1103927 (2023).","journal-title":"Front. Pharmacol."},{"key":"1583_CR26","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.2147\/DDDT.S162214","volume":"12","author":"H Yang","year":"2018","unstructured":"Yang, H. et al. Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. Drug Des. Devel Ther. 12, 2085\u20132096. https:\/\/doi.org\/10.2147\/DDDT.S162214 (2018).","journal-title":"Drug Des. Devel Ther."},{"key":"1583_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2147\/CCID.S451386","volume":"17","author":"DH Li","year":"2024","unstructured":"Li, D. H. & Xiong, X. Z. Immune checkpoint Inhibitor-Associated systemic sclerosis in the treatment of a small cell lung Cancer patient with durvalumab: A case report. Clin. Cosmet. Investig Dermatol. 17, 663\u2013669. https:\/\/doi.org\/10.2147\/CCID.S451386 (2024).","journal-title":"Clin. Cosmet. Investig Dermatol."},{"key":"1583_CR28","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.2147\/OTT.S178246","volume":"11","author":"W He","year":"2018","unstructured":"He, W. et al. Activated pulmonary tuberculosis in a patient with melanoma during PD-1 Inhibition: a case report. Onco Targets Ther. 11, 7423\u20137427. https:\/\/doi.org\/10.2147\/OTT.S178246 (2018).","journal-title":"Onco Targets Ther."},{"issue":"3","key":"1583_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/cco-23-153","volume":"13","author":"S Hirano","year":"2024","unstructured":"Hirano, S. et al. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment. Chin. Clin. Oncol. 13 (3), 43. https:\/\/doi.org\/10.21037\/cco-23-153 (2024).","journal-title":"Chin. Clin. Oncol."},{"issue":"4","key":"1583_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","volume":"55","author":"JJ Lee","year":"2016","unstructured":"Lee, J. J., Chan, A. & Tang, T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin\u2019s lymphoma. Acta Oncol. 55 (4), 519\u2013520. https:\/\/doi.org\/10.3109\/0284186X.2015.1125017 (2016).","journal-title":"Acta Oncol."},{"issue":"12","key":"1583_CR31","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","volume":"11","author":"K Fujita","year":"2016","unstructured":"Fujita, K., Terashima, T. & Mio, T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J. Thorac. Oncol. 11 (12), 2238\u20132240. https:\/\/doi.org\/10.1016\/j.jtho.2016.07.006 (2016).","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"1583_CR32","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","volume":"186","author":"DL Barber","year":"2011","unstructured":"Barber, D. L., Mayer-Barber, K. D., Feng, C. G., Sharpe, A. H. & Sher, A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated Inhibition. J. Immunol. 186 (3), 1598\u20131607. https:\/\/doi.org\/10.4049\/jimmunol.1003304 (2011).","journal-title":"J. Immunol."},{"issue":"5","key":"1583_CR33","doi-asserted-by":"publisher","first-page":"e1005667","DOI":"10.1371\/journal.ppat.1005667","volume":"12","author":"S Sakai","year":"2016","unstructured":"Sakai, S. et al. CD4 T Cell-Derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 12 (5), e1005667. https:\/\/doi.org\/10.1371\/journal.ppat.1005667 (2016).","journal-title":"PLoS Pathog"},{"key":"1583_CR34","doi-asserted-by":"publisher","unstructured":"Tezera, L. B. et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha. Elife 9. https:\/\/doi.org\/10.7554\/eLife.52668 (2020).","DOI":"10.7554\/eLife.52668"},{"issue":"1","key":"1583_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother Cancer. 6 (1), 56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9 (2018).","journal-title":"J. Immunother Cancer"},{"issue":"2","key":"1583_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jtho.2023.10.010","volume":"19","author":"Y Shiraishi","year":"2024","unstructured":"Shiraishi, Y. et al. Five cases of cytokine release syndrome in patients receiving cytotoxic chemotherapy together with nivolumab plus Ipilimumab: A case report. J. Thorac. Oncol. 19 (2), 337\u2013343. https:\/\/doi.org\/10.1016\/j.jtho.2023.10.010 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1583_CR37","doi-asserted-by":"publisher","first-page":"807050","DOI":"10.3389\/fimmu.2022.807050","volume":"13","author":"SH Tay","year":"2022","unstructured":"Tay, S. H. et al. Cytokine release syndrome in Cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature. Front. Immunol. 13, 807050. https:\/\/doi.org\/10.3389\/fimmu.2022.807050 (2022).","journal-title":"Front. Immunol."},{"issue":"2","key":"1583_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2), 188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729 (2014).","journal-title":"Blood"},{"key":"1583_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fphar.2020.00557","volume":"11","author":"A Ceschi","year":"2020","unstructured":"Ceschi, A., Noseda, R., Palin, K. & Verhamme, K. Immune checkpoint Inhibitor-Related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front. Pharmacol. 11, 557. https:\/\/doi.org\/10.3389\/fphar.2020.00557 (2020).","journal-title":"Front. Pharmacol."},{"issue":"8","key":"1583_CR40","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2020.7675","volume":"19","author":"K Panneerselvam","year":"2021","unstructured":"Panneerselvam, K. et al. Clinicopathologic features, treatment response, and outcomes of immune checkpoint Inhibitor-Related esophagitis. J. Natl. Compr. Canc Netw. 19 (8), 896\u2013904. https:\/\/doi.org\/10.6004\/jnccn.2020.7675 (2021).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"1583_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","volume":"6","author":"FZ Acero Brand","year":"2018","unstructured":"Acero Brand, F. Z. et al. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J. Immunother Cancer. 6 (1), 22. https:\/\/doi.org\/10.1186\/s40425-018-0332-z (2018).","journal-title":"J. Immunother Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01583-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01583-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:33:28Z","timestamp":1747157608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01583-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01583-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not required for this study because it used the FAERS database, which is a free open-access database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"16661"}}